Eli Lilly and Company (NYSE:LLY) is Private Advisory Group LLC's 5th Largest Position

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Private Advisory Group LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 8.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 35,282 shares of the company's stock after buying an additional 2,886 shares during the period. Eli Lilly and Company makes up about 3.3% of Private Advisory Group LLC's holdings, making the stock its 5th largest holding. Private Advisory Group LLC's holdings in Eli Lilly and Company were worth $29,140,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Natixis Advisors LLC lifted its stake in Eli Lilly and Company by 15.2% during the first quarter. Natixis Advisors LLC now owns 645,846 shares of the company's stock worth $533,411,000 after purchasing an additional 84,977 shares during the last quarter. NorthRock Partners LLC raised its holdings in shares of Eli Lilly and Company by 2.3% during the 1st quarter. NorthRock Partners LLC now owns 13,321 shares of the company's stock valued at $11,002,000 after buying an additional 299 shares in the last quarter. GS Investments Inc. purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at about $2,376,000. Bristol Gate Capital Partners Inc. bought a new stake in Eli Lilly and Company in the 1st quarter worth approximately $97,685,000. Finally, Baader Bank Aktiengesellschaft boosted its stake in Eli Lilly and Company by 23.3% in the first quarter. Baader Bank Aktiengesellschaft now owns 5,291 shares of the company's stock worth $4,238,000 after buying an additional 1,001 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 2.9%

Shares of LLY stock traded up $21.40 during trading hours on Friday, hitting $761.47. 4,857,388 shares of the company's stock traded hands, compared to its average volume of 3,285,034. The stock's fifty day simple moving average is $775.51 and its two-hundred day simple moving average is $799.86. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The stock has a market cap of $721.67 billion, a price-to-earnings ratio of 61.96, a PEG ratio of 1.05 and a beta of 0.44. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm's quarterly revenue was up 45.2% on a year-over-year basis. During the same period last year, the business earned $2.58 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price target for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $1,012.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.